Brian T. Lee
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (17)
Year:
2026
Year:
2026
INTRODUCTION: Alcohol-associated liver disease (ALD) is a common cause of morbidity and premature mortality. Most prognostic scores have been defined in the short term. We used a large retrospective cohort of patients with ALD to describe the natural history of ALD and to define risk prediction in the longer term, taking nonliver mortality into account. METHODS: The WALDO cohort includes 734 patients with biopsy-proven ALD. Prognostic scores were assessed with dynamic area under the curve and C-index. Risk estimates for morbidity and mortality were derived for the model for end-stage liver disease (MELD) and validated in an external cohort. RESULTS: During a median follow-up of 4.9 years, 240 patients died from liver disease or underwent liver transplantation (LT), and 114 patients died from nonliver causes. Outcomes varied across the spectrum of ALD: The cumulative incidence of liver-related death or LT in people with decompensated cirrhosis or alcohol-associated hepatitis was 47% and 40%, respectively, compared with 7.4% in patients without cirrhosis and 13% in compensated cirrhosis. MELD was the best predictor of outcomes: (area under the curve for mortality/LT at 1 year was 0.853), although MELD3.0 and the Child-Turcotte-Pugh score performed similarly. Risk of liver-related outcomes were tabulated for integer values of the MELD score. Risk estimates based on the MELD were well calibrated in an external cohort. DISCUSSION: These data illustrate the natural history of ALD and define the risks of outcomes based on the MELD score across the spectrum of disease.
Year:
2025
Background Criteria for simultaneous liver kidney transplantation (SLKT) have undergone several iterations. In August 2017, the Organ Procurement Transplantation Network (OPTN) created specific criteria for SLKT allocation and established a “safety net” protocol to allocate kidney allografts for liver transplant recipients with persistent renal dysfunction within the first year after liver transplantation (KALT). Published studies that evaluated patient and kidney allograft survival have applied the “safety net” criteria retrospectively to time periods prior to enactment of the policy. We aimed to assess kidney allograft outcomes in those who underwent KALT compared to those who underwent SLKT during the actual “safety net” era. Methods This retrospective cohort study included adults (≥18 years) receiving a primary kidney transplant via SLKT or safety net KALT from 2018 to 2021, captured in the OPTN database. Patients receiving multiple organs other than kidney‐liver, a kidney from a living donor, a split liver, or sequential or en bloc kidney transplant were excluded. Study outcomes, including kidney allograft survival, patient survival, eGFR and kidney rejection, were compared by KALT versus SLKT post‐kidney transplant. Differences in eGFR and rejection for KALT versus SLKT were then assessed in a propensity score analysis (nearest neighbor matching [ n = 4]) to estimate the conditional average treatment effect. Results Between January 2018 and December 2021, 2620 patients underwent SLKT, and 526 underwent KALT by the safety net policy. Those who underwent KALT had a lower prevalence of diabetes mellitus (36.3% vs. 43.2%, p = 0.003). Alcohol as a reason for liver transplantation was higher in KALT versus SLKT (43.0 vs. 30.8%, p < 0.001). Recipients of KALT compared to SLKT had a higher prevalence of dialysis prior to transplant (73.2% vs. 53.5%, p < 0.001) with a higher median number of months of dialysis time (9.0 vs. 4.9 months, p < 0.001). At 1‐year post‐kidney transplant, KALT versus SLKT observed similar kidney allograft survival rates (97.7% [95%CI 96.0–98.7] vs. 96.8% [95%CI 96.0–97.4], p = 0.43) but higher patient survival rates (96.7% [95%CI 94.8–98.0] vs. 93.9% [95%CI 92.9–94.8] at 1 year [ p = 0.02]). Those with KALT consistently had lower eGFR at 6 months, 1 year, and 3 years after kidney transplantation. The mean difference at 1 year was −6.6 mL/min/1.73 m 2 (95% CI: −8.5 to −4.7, p < 0.001) in the unadjusted and −4.7 mL/min/1.73 m 2 (95% CI: −7.0 to −2.4, p < 0.001) in the propensity score matched analysis. At the longest follow‐up of 3 years, the mean difference remained −6.3 mL/min/1.73 m 2 (95%CI: −8.8 to −3.7, p < 0.001) in the unadjusted and −3.8 mL/min/1.73 m 2 (95% CI: −6.5 to −1.1, p = 0.005) in the propensity score matched analysis. While those with KALT had higher observed rates of rejection than SLKT throughout the period of 6 months, 1 year, and 3 years, propensity score matched analyses (adjusting for age, cPRA, HLA mismatch) did not show significant differences in rejection at all time points. Conclusion While kidney allograft survival was similar, KALT recipients had significantly lower eGFR than their SLKT counterparts. Currently, there are inadequate data to determine if these findings can be attributed to differences in rejection rates, and longer‐term follow‐up of kidney allograft outcomes is needed.
Year:
2025
Lutetium-177 vipivotide tetraxetan (LuPSMA) is a small molecule inhibitor with high affinity to prostate-specific membrane antigen and is currently used in the treatment of metastatic castrate-resistant prostate cancer. Hepatotoxicity has seldom been reported. This is a case of drug-induced liver injury presenting in a patient who received 5 cycles of LuPSMA for metastatic castrate-resistant prostate cancer. In this report, we provide a probable case of drug-induced liver injury with imaging and histologic findings of cholestatic liver injury and stricturing cholangiopathy related to LuPSMA. This is the first report of LuPSMA as a probable cause of hepatotoxicity.
Year:
2025
Goals: Our aim was to perform a national survey of provider attitudes, practices, and knowledge regarding weight loss and MASLD medications in patients with MASLD. Background: While weight loss is a cornerstone in the management of metabolic dysfunction-associated steatotic liver disease (MASLD), FDA-approved medications for weight loss remain underutilized. Results: We conducted a survey before resmetirom approval of hepatology and gastroenterology providers practicing in 44 states. Surveys were sent to 747 providers with 304 complete responses (41%), of whom 260 (86%) work at a liver transplant center. While nearly all respondents (96%) believed that weight loss medications could benefit patients with MASLD, 77% have never/rarely prescribed them due to low comfort (81%). Among weight loss medication prescribers, glucagon-like peptide-1 (GLP-1) receptor agonists were preferred (66%). In contrast, 63% had prescribed off-label medications for MASLD in the past 12 months, most commonly vitamin E (30%) and GLP-1 receptor agonists (25%). The top reported barriers to prescribing weight loss medications were lack of training/unfamiliarity, cost/insurance coverage, and side-effects, which may be explained by low formal obesity education and lack of knowledge (only 33% of FDA-approved medications for weight loss were correctly identified by >50% of providers). Overall, there was reasonable provider-reported adherence to the 2023 AASLD practice guidance for MASLD. Conclusions: This nationwide survey of hepatology and gastroenterology providers before resmetirom demonstrates that while off-label prescribing for MASLD was common, weight loss medication prescription rates remain very low due to low comfort possibly from insufficient education despite strong beliefs that they can benefit patients with MASLD.
Year:
2025
Background. MELD 3.0 introduces changes to address waitlist disparities for liver transplant (LT) candidates. Ascites and hepatic encephalopathy (HE) are important milestones in the natural history of cirrhosis regardless of the Model for End-Stage Liver Disease (MELD) score. We aim to assess the impact of ascites and HE and its interaction with MELD 3.0 on waitlist mortality. Methods. This is a retrospective study of patients listed for LT in the Organ Procurement and Transplantation Network database from 2016 to 2021. The primary outcome was waitlist mortality (death/delisting for too sick to LT). Ascites/HE were classified as moderate ascites without moderate HE (mAscites), moderate HE without moderate ascites (mHE), both moderate ascites/HE (mBoth), and neither. MELD 3.0 scores were categorized as <20, 20–29, 30–39, and ≥40. Results. Of 39 025 candidates, 29% had mAscites, 3% mHE, and 8% mBoth. One-year waitlist mortality was 30%, 38%, and 47%, respectively, compared with 17% (all P < 0.001) for those with neither. In multivariable Cox regression, the adjusted risk of waitlist mortality associated with mAscites (versus neither) was a hazard ratio (HR) of 1.76 (95% confidence interval [CI], 1.55-2.00) when the MELD 3.0 score was <20, significantly higher than when the MELD 3.0 score was 20–29 (HR 1.40; 95% CI, 1.27-1.54), 30–39 (HR 1.19; 95% CI, 1.04-1.35), and ≥40 (HR 1.14; 95% CI, 0.91-1.43, interaction P < 0.05 for all). A similar pattern was observed by MELD 3.0 for both moderate ascites/HE. Conclusions. The presence of moderate ascites alone, or combined with moderate HE, not only increases the risk of waitlist mortality but also has a differential effect by MELD 3.0, especially at lower MELD scores. Earlier strategies addressing this group and improving treatment plans or access to LT regardless of MELD remain needed.
Year:
2024
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Collaborators (8)
Thomas Cotter
Principal Investigator
University of Texas Southwestern Medical Center
Richard Parker
-
Elizabeth Aby
Faculty, Assistant Professor
University of Minnesota
Guruprasad P. Aithal
Professor of Hepatology
University of Nottingham
Lily Dara
University of Southern California
Hannes Hagström
Professor, Senior Consultant Hepatologist
Karolinska Institutet
Jennifer Dodge
Associate Professor
University of Southern California
Mohamed Elfeki
Assistant Professor
South Dakota State University
Make your next move.
Prepare your application
Review drafts before you send them.